Single‐Dose Rasburicase 6 mg in the Management of Tumor Lysis Syndrome in Adults

@article{McDonnell2006SingleDoseR6,
  title={Single‐Dose Rasburicase 6 mg in the Management of Tumor Lysis Syndrome in Adults},
  author={A. McDonnell and K. L. Lenz and D. Frei‐Lahr and J. Hayslip and P. Hall},
  journal={Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year={2006},
  volume={26}
}
  • A. McDonnell, K. L. Lenz, +2 authors P. Hall
  • Published 2006
  • Medicine
  • Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
  • Rasburicase is currently approved at a dosage of 0.15–0.2 mg/kg once/day for 5 days in pediatric patients with cancer to lower plasma uric acid concentrations and manage tumor lysis syndrome (TLS). Information on rasburicase dosing in adults is limited, with some data on using rasburicase as a single dose instead of multiple daily doses. Therefore, we evaluated the efficacy of a single dose of rasburicase for preventing or managing TLS in adults. We collected retrospective data for 11 adults… CONTINUE READING
    64 Citations
    Single 6-mg dose of rasburicase: The experience in a large academic medical center
    • 3
    A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.
    • 64
    Reduced administration of rasburicase for tumor lysis syndrome: A single-institution experience.
    • 3
    • PDF
    Fixed, low-dose rasburicase for the treatment or prevention of hyperuricemia in adult oncology patients
    • J. Herrington, Brian C Dinh
    • Medicine
    • Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
    • 2015
    • 19
    A single, fixed dose of rasburicase (6 mg maximum) for treatment of tumor lysis syndrome in adults
    • 28
    Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome
    • R. Knoebel, M. Lo, C. Crank
    • Medicine
    • Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
    • 2011
    • 30
    Rasburicase and tumor lysis syndrome: lower dosage, consideration of indications, and hyperhydration.
    • 17

    References

    SHOWING 1-10 OF 15 REFERENCES
    Use of Single-Dose Rasburicase in an Obese Female
    • 26
    Treatment of Impending Tumor Lysis with Single-Dose Rasburicase
    • 55
    • Highly Influential
    Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma.
    • C. Pui, H. Mahmoud, +7 authors G. Reaman
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2001
    • 300
    Tumor lysis syndrome.
    • 133
    Tumor lysis syndrome.
    • 325